Lapelga (pegfilgrastim)

pCPA File Number: 22352
Negotiation Status:
Concluded with an LOI
Indication(s):
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Sponsor/Manufacturer:
Apobiologix, a Division of Apotex Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: